Jamshedpur Reporter

Acute Ischemic Stroke Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

 Breaking News
  • No posts were found

Acute Ischemic Stroke Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

September 15
21:37 2022
Acute Ischemic Stroke Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Acute Ischemic Stroke pipeline constitutes 35+ key companies continuously working towards developing 35+ Acute Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Acute Ischemic Stroke Overview

Acute Ischemic Stroke occurs when blood flow through a brain artery is blocked by a clot- a mass of thickened blood. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, the more common of the two, occurs when a clot forms within an artery in the brain. Almost half of all acute ischemic strokes are due to large vessel occlusion (LVO). Ischemic stroke can be divided into two main types: thrombotic and embolic.

“Acute Ischemic Stroke Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Ischemic Stroke Market. 

The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Acute Ischemic Stroke Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Acute Ischemic Stroke treatment therapies with a considerable amount of success over the years. Acute Ischemic Stroke Key players such as – Prolong Pharmaceuticals, Meridigen Biotech, Techfields Pharma, Biogen, Shin Poong Pharmaceutical, NuvOx LLC, Acticor Biotech, Athersys,  NoNO Inc., and others, are developing therapies for the Acute Ischemic Stroke treatment 
  • Acute Ischemic Stroke Emerging therapies such as – PP 007 , UMC 119 06, TF 0023, BIIB131, SP-8203, NVX-108, Glenzocimab, Invimestrocel, Nerinetide, and others are expected to have a significant impact on the Acute Ischemic Stroke market in the coming years.   
  • In October 2016, Arbor Vita Corporation, a U.S.-based biotechnology company, and NoNO, Inc biotechnology company focused on neurological diseases, announced their partnership for the development and commercialization of drugs for the treatment of stroke. The research and development collaboration combines Arbor Vita’s PDZ-based Drug Discovery Platform with NoNO’s expertise in the area of neurological disorders.
  • In March 2017, NoNO Inc initiated a Phase III, multicentre, randomized, double-blinded,placebo-controlled, parallel-group single-dose design to determine the efficacy and safety of intravenousna-1 in subjects with acute ischemic stroke undergoing endovascular thrombectomy
  • In December 2020, NoNO Inc initiated a multicentre, randomized, double-blinded,placebo-controlled, parallel-group, single-dose design to determine the efficacy and safety of Nerinetide in participants with acute ischemic stroke undergoing endovascular thrombectomy excluding thrombolysis 

 

Acute Ischemic Stroke Pipeline Therapeutics Assessment 

  • Acute Ischemic Stroke Assessment by Product Type
  • Acute Ischemic Stroke By Stage and Product Type
  • Acute Ischemic Stroke Assessment by Route of Administration
  • Acute Ischemic Stroke By Stage and Route of Administration
  • Acute Ischemic Stroke Assessment by Molecule Type
  • Acute Ischemic Stroke by Stage and Molecule Type 

 

DelveInsight’s Acute Ischemic Stroke Report covers around 35+ products under different phases of clinical development like 

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Acute Ischemic Stroke Drugs Under Different Phases of Clinical Development Include: 

  • PP 007: Prolong Pharmaceuticals
  • UMC 119 06: Meridigen Biotech
  • TF 0023: Techfields Pharma
  • BIIB131: Biogen
  • SP-8203: Shin Poong Pharmaceutical
  • NVX-108: NuvOx LLC
  • Glenzocimab: Acticor Biotech
  • Invimestrocel: Athersys
  • Nerinetide: NoNO

 

Further Acute Ischemic Stroke product details are provided in the report. Download the Acute Ischemic Stroke pipeline report to learn more about the emerging Acute Ischemic Stroke therapies

 

Acute Ischemic Stroke Pipeline Analysis:

The Acute Ischemic Stroke pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Acute Ischemic Stroke treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Ischemic Stroke Treatment.
  • Acute Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Acute Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Acute Ischemic Stroke Pipeline Market Drivers

  • Increasing prevalence of Acute Ischemic Stroke
  • The rising of global health awareness

 

Acute Ischemic Stroke Pipeline Market Barriers

  • Lack of novel Acute Ischemic Stroke therapies

 

Get a Free Sample PDF Report to know more about Acute Ischemic Stroke Pipeline Assessment

 

Scope of Acute Ischemic Stroke Pipeline Drug Insight    

  • Coverage: Global
  • Key Acute Ischemic Stroke Companies: Prolong Pharmaceuticals, Meridigen Biotech, Techfields Pharma, Biogen,Shin Poong Pharmaceutical, NuvOx LLC, Acticor Biotech, Athersys,  NoNO Inc., and others
  • Key Acute Ischemic Stroke Therapies: PP 007 , UMC 119 06, TF 0023, BIIB131, SP-8203 , NVX-108, Glenzocimab, Invimestrocel, Nerinetide, and others
  • Acute Ischemic Stroke Therapeutic Assessment: Acute Ischemic Stroke current marketed and Acute Ischemic Stroke emerging therapies
  • Acute Ischemic Stroke Market Dynamics:  Acute Ischemic Stroke market drivers and Acute Ischemic Stroke market barriers 

 

Request for Sample PDF Report for Acute Ischemic Stroke Pipeline Assessment and clinical trials

 

Table of Contents

1

Acute Ischemic Stroke Report Introduction

2

Acute Ischemic Stroke Executive Summary

3

Acute Ischemic Stroke Overview

4

Acute Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment

5

Acute Ischemic Stroke Pipeline Therapeutics

6

Acute Ischemic Stroke Late Stage Products (Phase II/III)

7

Acute Ischemic Stroke Mid Stage Products (Phase II)

8

Acute Ischemic Stroke Early Stage Products (Phase I)

9

Acute Ischemic Stroke Preclinical Stage Products

10

Acute Ischemic Stroke Therapeutics Assessment

11

Acute Ischemic Stroke Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Acute Ischemic Stroke Key Companies

14

Acute Ischemic Stroke Key Products

15

Acute Ischemic Stroke Unmet Needs

16 

Acute Ischemic Stroke Market Drivers and Barriers

17

Acute Ischemic Stroke Future Perspectives and Conclusion

18

Acute Ischemic Stroke Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Acute Ischemic Stroke drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/